Description

INTACOXIA 60 MG

Indications

INTACOXIA 60 MG is primarily indicated for the management of pain and inflammation associated with various conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also used in the treatment of acute pain, particularly post-operative pain, and in conditions where non-steroidal anti-inflammatory drugs (NSAIDs) are indicated.

Mechanism of Action

INTACOXIA contains the active ingredient etoricoxib, which is a selective inhibitor of cyclooxygenase-2 (COX-2). By selectively inhibiting COX-2, INTACOXIA reduces the synthesis of prostaglandins, which are mediators of inflammation and pain. This mechanism leads to a decrease in pain and inflammation without significantly affecting COX-1, which is involved in the maintenance of gastric mucosa and platelet function. As a result, INTACOXIA has a lower risk of gastrointestinal side effects compared to traditional NSAIDs.

Pharmacological Properties

INTACOXIA is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 1 to 3 hours post-dose. The drug has a bioavailability of about 100%, and its effects can last for up to 24 hours, allowing for once-daily dosing. INTACOXIA is primarily metabolized in the liver via cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, and its metabolites are excreted mainly in the urine. The elimination half-life of etoricoxib is approximately 22 hours, making it suitable for once-daily administration.

Contraindications

INTACOXIA is contraindicated in patients with a known hypersensitivity to etoricoxib or any of its excipients. It should not be used in individuals with a history of allergic reactions to sulfonamides. Additionally, INTACOXIA is contraindicated in patients with severe hepatic impairment, active peptic ulcer disease, or a history of gastrointestinal bleeding. It is also not recommended for use in patients with significant cardiovascular disease, as it may increase the risk of thrombotic events.

Side Effects

Common side effects associated with INTACOXIA include headache, dizziness, gastrointestinal discomfort, and hypertension. Serious side effects may include cardiovascular events such as myocardial infarction and stroke, renal impairment, and liver function abnormalities. Patients should be monitored for signs of gastrointestinal bleeding, especially if they have a history of peptic ulcer disease. If any severe side effects occur, patients should seek immediate medical attention.

Dosage and Administration

The recommended dose of INTACOXIA for adults is 60 mg once daily for the treatment of osteoarthritis and acute pain. For rheumatoid arthritis and ankylosing spondylitis, the dosage may be increased to 90 mg once daily if necessary. It is important to take INTACOXIA at the same time each day, with or without food. Dosage adjustments may be required for patients with mild to moderate hepatic impairment, and the use of INTACOXIA is not recommended in patients with severe hepatic impairment.

Interactions

INTACOXIA may interact with other medications, particularly those that are metabolized by the liver. Co-administration with strong CYP2D6 or CYP3A4 inhibitors may increase plasma concentrations of etoricoxib, necessitating dosage adjustments. Additionally, concurrent use of other NSAIDs or anticoagulants may increase the risk of gastrointestinal bleeding. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions.

Precautions

Patients taking INTACOXIA should be monitored for signs of cardiovascular events, especially those with pre-existing cardiovascular conditions. Caution is advised in patients with a history of hypertension, renal impairment, or liver disease. It is recommended to perform regular blood pressure checks and renal function tests during treatment. Pregnant and breastfeeding women should consult their healthcare provider before using INTACOXIA, as its safety in these populations has not been established.

Clinical Studies

Clinical studies have demonstrated the efficacy of INTACOXIA in reducing pain and improving function in patients with osteoarthritis and rheumatoid arthritis. In a randomized, double-blind study, patients receiving INTACOXIA showed significant improvements in pain scores compared to those receiving placebo. Furthermore, long-term studies have indicated that INTACOXIA is effective in managing chronic pain conditions with a favorable safety profile compared to traditional NSAIDs. Ongoing research continues to evaluate its long-term effects and safety in various populations.

Conclusion

INTACOXIA 60 MG is an effective option for the management of pain and inflammation in various musculoskeletal conditions. Its selective inhibition of COX-2 provides significant analgesic and anti-inflammatory effects while minimizing gastrointestinal side effects commonly associated with non-selective NSAIDs. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should always consult their healthcare provider for personalized medical advice and treatment plans.